title: [Role of cyclic nucleotide phosphodiesterases in the cAMP compartmentation in cardiac cells].
abstract: In the light of the knowledge accumulated over the years, it becomes clear that intracellular cAMP is not uniformly distributed within cardiomyocytes and that cAMP compartmentation is required for adequate processing and targeting of the information generated at the membrane. Localized cAMP signals may be generated by interplay between discrete production sites and restricted diffusion within the cytoplasm. In addition to specialized membrane structures that may limit cAMP spreading, degradation of the second messenger by cyclic nucleotide phosphodiesterases (PDEs) appears critical for the formation of dynamic microdomains that confer specificity of the response to various hormones. This review summarizes the main findings that support the cAMP compartmentation hypothesis in cardiac cells, with a special emphasis on PDEs. The respective roles of the four main cardiac cAMP-PDE families (PDE1 to PDE4) in the organization of cAMP microdomains and hormonal specificity in cardiac cells are reviewed. The evidence that these PDEs are modified in heart failure is summarized, and the implication for the progression of the disease is discussed. Finally, the potential benefits that could be awaited from the manipulation of specific PDE subtypes in heart failure are presented.
authors.affiliation: Inserm UMR-S 769- LabEx LERMIT, 92296 Châtenay-Malabry, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Mika
authors.forename: Jérôme
authors.initials: J
authors.lastname: Leroy
authors.forename: Grégoire
authors.initials: G
authors.lastname: Vandecasteele
authors.forename: Rodolphe
authors.initials: R
authors.lastname: Fischmeister
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000145:classification / Q000502:physiology*; D000818:Animals; D002451:Cell Compartmentation; D000242:Cyclic AMP / Q000378:metabolism*; D054677:Cyclic Nucleotide Phosphodiesterases, Type 1 / Q000502:physiology; D054678:Cyclic Nucleotide Phosphodiesterases, Type 2 / Q000502:physiology; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3 / Q000502:physiology; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000502:physiology; D006333:Heart Failure / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D007473:Ion Channels / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D058990:Molecular Targeted Therapy; D032383:Myocytes, Cardiac / Q000201:enzymology* / Q000648:ultrastructure; D015290:Second Messenger Systems
chemical_list: D007473:Ion Channels; D000242:Cyclic AMP; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054677:Cyclic Nucleotide Phosphodiesterases, Type 1; D054678:Cyclic Nucleotide Phosphodiesterases, Type 2; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4